Bioventus (NASDAQ:BVS) & Tactile Systems Technology (NASDAQ:TCMD) Head-To-Head Review

Bioventus (NASDAQ:BVS) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Valuation and Earnings

This table compares Bioventus and Tactile Systems Technology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09 million	1.63	$22.73 million	$0.80	13.77
Tactile Systems Technology	$329.52 million	1.80	$19.09 million	$1.03	25.82

Bioventus has higher revenue and earnings than Tactile Systems Technology. Bioventus is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Bioventus and Tactile Systems Technology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	1	5	0	2.83
Tactile Systems Technology	0	2	4	0	2.67

Bioventus currently has a consensus price target of $16.60, suggesting a potential upside of 50.64%. Tactile Systems Technology has a consensus price target of $36.80, suggesting a potential upside of 38.40%. Given Bioventus’ stronger consensus rating and higher possible upside, research analysts plainly believe Bioventus is more favorable than Tactile Systems Technology.

Risk & Volatility

Bioventus has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Profitability

This table compares Bioventus and Tactile Systems Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	9.78%	26.31%	10.13%
Tactile Systems Technology	6.68%	10.73%	8.53%

Institutional and Insider Ownership

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are owned by institutional investors. 33.5% of Bioventus shares are owned by insiders. Comparatively, 2.1% of Tactile Systems Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Bioventus beats Tactile Systems Technology on 9 of the 14 factors compared between the two stocks.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About Tactile Systems Technology

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.